Event: Biosimilars Asia 2010
Dates: May 31 - June 1, 2010
Venue: Grand Hyatt, Shanghai, China
Contact: Mary Anuilar
Tel: +65 6514 3172
Weblink: www.ibc-asia.com/biosimilars

Today, total sales of off-patent biologics amount to approximately US$20 billion, of which Asia is the primary market, accounting for 34% of sales. This number is expected to increase considerably, opening up investment opportunities for both pharmaceutical and generic companies.

However, the dynamics of biosimilars presents a greater challenge than classic generics, requiring significant investments and risks, forcing producers to make careful selections on protein classes, building up new competencies and developing new models for cooperation. In general, the main differentiators for leaders in the biosimilars market will be safety, efficacy and convenience of their products and to a lesser extent the price of their drugs.

Biosimilars Asia 2010, taking place May 31 - June 1, 2010 in Shanghai, China, is Asia’s ONLY forum for innovators, leaders in generics and regulators focused on biosimilars. This is an excellent platform to understand latest global developments in biosimilars and access key regulatory and scientific concerns impacting biosimilars.

To register, please call Mary Aguilar +65 6514 3172/Customer service on 65 6514 3180 or visit www.ibc-asia.com/biosimilars.